Farther Finance Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $116K | Buy |
919
+233
| +34% | +$29.3K | ﹤0.01% | 1683 |
|
|
2025
Q1 | $73.4K | Buy |
686
+193
| +39% | +$20.7K | ﹤0.01% | 1686 |
|
|
2024
Q4 | $67.3K | Buy |
493
+51
| +12% | +$6.96K | ﹤0.01% | 1502 |
|
|
2024
Q3 | $50.9K | Hold |
442
| – | – | ﹤0.01% | 1638 |
|
|
2024
Q2 | $61.9K | Buy |
442
+7
| +2% | +$981 | ﹤0.01% | 1329 |
|
|
2024
Q1 | $61.5K | Buy |
435
+5
| +1% | +$707 | ﹤0.01% | 1110 |
|
|
2023
Q4 | $56.7K | Buy |
430
+7
| +2% | +$922 | ﹤0.01% | 994 |
|
|
2023
Q3 | $47.6K | Buy |
423
+413
| +4,130% | +$46.5K | 0.01% | 789 |
|
|
2023
Q2 | $943 | Buy |
10
+5
| +100% | +$472 | ﹤0.01% | 1994 |
|
|
2023
Q1 | $506 | Hold |
5
| – | – | ﹤0.01% | 2002 |
|
|
2022
Q4 | $597 | Buy |
+5
| New | +$597 | ﹤0.01% | 1799 |
|